Vertex Pharmaceuticals Change in Prepaid Expenses and Other Assets remained flat by 0.0% to $99.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 97.7%, from $50.08M to $99.00M. Over 2 years (FY 2023 to FY 2025), Change in Prepaid Expenses and Other Assets shows a downward trend with a -14.8% CAGR.
Significant fluctuations can indicate changes in procurement timing or prepayments for large-scale clinical trials or supply contracts.
This reflects the net change in payments made in advance for goods or services to be received in future periods, along w...
Standard working capital metric; common across all industries to track short-term asset management.
is_cvx_change_in_prepaid_expenses_and_other_assets| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $545.70M | $200.30M | $396.00M |
| YoY Change | — | -63.3% | +97.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.